The University of Cincinnati is joining a nationwide study to evaluate repurposed medications in the search for effective, safe treatments for mild-to-moderate COVID-19. Repurposed medications are those already approved by the U.S. Food and Drug Administration for other indications.
ACTIV-6, "The Randomized Trial to Evaluate Efficacy of Repurposed Medications," is a nationwide double-blind study expected to enroll nearly 15,000 participants from across the United States through its website.
The study recently expanded its testing platform to evaluate three repurposed medications in the search for effective, safe treatments for mild-to-moderate COVID-19. Web and phone-based enrollment allows people anywhere in the United States diagnosed with COVID-19 as outpatients to help test potential COVID-19 treatments without leaving home.
"Not only does the ACTIV-6 study help answer important questions related to treatment options for mild-to-moderate COVID-19, but it also does so in a way that increases the accessibility of clinical trials to our community members," says Margaret Powers-Fletcher, PhD, assistant professor in the Division of Infectious Diseases in the Department of Internal Medicine at the UC College of Medicine and principal investigator of the ACTIV-6 study at UC. "This improves our ability to all work together toward medical advancement and scientific discovery in the face of a continued public health crisis."
